Akumin — FY2022 Earnings Presentation
19 slides from Akumin's earnings presentation, Mar 17, 2023
Slide 1: Q4 and Full-Year 2022 Results
Akumin Inc. Q4 and Full-Year 2022 Results March 17, 2023 Riadh Zine, Chairman & CEO David Kretschmer, Chief Financial Officer
Slide 2: Disclaimer and Disclosure
Disclaimer and Disclosure Forward-Looking Statements This presentation may contain forward-looking information or forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995 and/or applicable Canadian securities legislation (collectively, “forward-looki
Slide 3: The Partner of Choice for Hospitals and Health systems
Our Vision: The Partner of Choice for Hospitals and Health systems Hospital & health Currently serving ~1,100 systems make up 23 of the 30 largest U.S. hospital relationships ~50% of current health systems are in 48 states revenue - we plan customers today to grow this significantly AKUMIN | 3
Slide 4: Akumin is an outpatient solutions provider for hospitals & health systems
Akumin is an outpatient solutions provider for hospitals & health systems HOPD oncology Mobile facilities MRI The Akumin value prop with a patient-centric approach Network coverage: Integrated service delivery with health systems in a patient community Patented JVs, MSAs, HOPD fixed- Clinical st
Slide 5: 2022: Organizational Transformation, Industry Challenges
2022: Organizational Transformation, Industry Challenges Transformation impact: Restructured the organization, implemented ~$20M of organizational savings and brought on several new executives in key areas of the business Consolidation of Radiology sites: Unprofitable fixed sites were rationaliz
Slide 6: Revenue Decomposition
Revenue Decomposition FY2021 pro forma to FY2022 Increase Decrease Revenue decomposition, $M -7.5 749.6 19.6 727.1 10.4 FY 2021 Pro Forma Specialty FDC Tracers Radiology Revenues Oncology Revenues FY 2022 Actual Total Revenue (Pass Through) Total Revenue Specialty tracer cost increases were reimbu
Slide 7: Cost of operations and other adj. decomposition (FY2021 to FY2022)
Cost of operations and other adj. decomposition (FY2021 to FY2022) Cost of operations1 and other adjustments decomposition by metric ($M) Increase Decrease $605.5 $8.1 $2.4 $3.3 $9.0 $11.9 $580.3 Specialty FDG Tracer (pass through) $10.4 -$11.0 Other medical supplies $1.5 $1.6 FY2021 Actual Employee
Slide 8: Significant Operating Leverage
Significant Operating Leverage Significant Operating Leverage from Organic Growth Current Incremental Base Organic Net Revenue: $ 1.00 $ 1.00 Cost Element Cost Nature % of Net Revenue Employee Compensation(1) Variable 37% $ (0.37) $ (0.37) Reading Fees Variable 6% $ (0.06) $ (0.06) Rent and Utilitie
Slide 9: Opportunities Ahead: 2023 and Beyond
Opportunities Ahead: 2023 and Beyond Additional integration synergies: Rationalizing business processes, consolidating IT systems and equipment maintenance services Workforce productivity gains: Specific focus on improving scans / treatments per worked hour Same-store growth via commercial & o
Slide 10: Q4 2022 Performance Highlights
Same Store Volumes on a pro forma basis across the platform continued to trend positively: MRI: -0.3% PET/CT: +7.8% Total Oncology Patient Starts: +8.0% Q4 2022 Performance Revenue of $184.6M, up 2.9% vs. Q4 2021. Highlights Adjusted EBITDA1 of $37.4M, up 36% vs. Q4 2021. Adjusted EBITDA
Slide 11: Diverse Service Lines and Modalities
Diverse Service Lines and Modalities Service Lines (% of Revenue) 1 Radiology Procedure Mix Diversification of revenue (% of Revenue) between Radiology and Oncology divisions 21% Akumin provides a full suite of 54% radiology and oncology services 25% with a focus on high-growth and high-value modali
Slide 12: Diverse Payor Mix
Diverse Payor Mix FY2022 Payor Mix1, % of Revenue of the company’s overall ~95% revenue is derived from outpatient procedures 51% 49% of revenue is received of revenue is received via third party and via health systems government payors, and hospitals, of which and reimbursed at virtually all is for
Slide 13: Volume Trends
Volume Trends Total Volumes, # of procedures / patient starts MRI, #K procedures PET/CT, #K procedures 2.8 Oncology, #K patient starts 2.8 230.0 225.3 35.0 2.7 225.0 2.623 219.8 34.5 33.7 2.7 2.588 2.592 34.0 33.4 33.4 220.0 … 216.4 33.5 2.6 2.544 214.2 33.0 2.6 215.0 32.5 32.0 2.5 210.0 32.0 2.5 31
Slide 14: Segment Financial Performance
Segment Financial Performance Annual Pro Forma1 Revenue (M) Adj. EBITDA2 and Margin Pro Forma1 (M) Oncology Radiology Overall margin EBITDA $750 21.6% $727 $678 20.1% 19.2% $125 $132 $129 $146 $146 $144 $595 $625 $549 2020 2021 2022 2020 2021 2022 Source: Company financial reports. 1. Pro forma resu
Slide 15: Free Cash Flows (FY2022)
Free Cash Flows (FY2022) Free Cash Flow (FY 2022) ($M) $144.1M -$65.9M Increase Decrease -$28.1M -$24.1M -$10.9M $11.0M -$8.3M -$1.7M -$5.9M Adjusted Cash Interest Cash Minority Capital Working Cash Capex Cash-Related Other Annual EBITDA Interest Lease & LT Capital payments Non- Cash Flow Debt recur
Slide 16: 2023 Guidance
We expect 2023 results as follows: Revenue range $765M-$775M Adjusted EBITDA1 range $150M-$160M Total CAPEX spend of ~$55-$65M: 2023 Guidance ‒ ~$20-$30M earmarked for growth capex for new customers and new sites ‒ Total capex to be funded with approx. 20% in cash and the balance financed 1. S
Slide 17: Capital Structure – A Solid Foundation for Growth
Capital Structure – A Solid Foundation Adjusted EBITDA1 $155.0 for Growth Total Secured Debt $922.8 Akumin’s capital structure is comprised of a diverse set of capital providers Less: Cash 59.4 including traditional banks, bondholders and Stonepeak as debt and equity Net Secured Debt $863.4 stakehol
Slide 18: Thank you!
Thank you! Riadh Zine, Chairman & CEO David Kretschmer, Chief Financial Officer
Slide 19: Appendix 1: Reconciliation of Net Loss to Adjusted EBITDA
Appendix 1: Reconciliation of Net Loss to Adjusted EBITDA Three-month Three-month period ended period ended Year ended Year ended Dec 31, 2022 Dec 31, 2021 Dec 31, 2022 Dec 31, 2021 Net Loss $ (49,331) $ (26,632) $ (151,587) $ (34,814) Interest expense 30,362 28,354 118,012 62,575 Income tax expense